ARDAN Pharma is developing a First-in-Class immunotherapy focused on the problem of therapeutic resistance in cancer patients. We have identified drug candidates that induce pharmacologic inhibition of TMEM176B/A, an emerging oncology target, a potential biomarker, and resistance factor to current immunotherapies.

Our target selection relies on its ability to modulate the tumor microenvironment, enhance anti-tumor responses while simultaneously promoting tumor-cell death.